2B4 Stock Overview An orthobiologics company, develops and commercializes injectable bio-ceramic bone graft substitutes in Europe, North America, and internationally. More details
Rewards Risk Analysis See All Risk Checks Capture your thoughts, links and company narrative
Bonesupport Holding AB (publ) Competitors Price History & Performance
Summary of share price highs, lows and changes for Bonesupport Holding Historical stock prices Current Share Price SEK 29.76 52 Week High SEK 39.42 52 Week Low SEK 15.20 Beta 0.99 1 Month Change -12.98% 3 Month Change 6.29% 1 Year Change 64.24% 3 Year Change 727.82% 5 Year Change 760.12% Change since IPO 908.47%
Recent News & Updates
Bonesupport Holding AB (publ) Announces Study Results for CERAMENT G and CERAMENT V in Surgical Treatment of Bone Infection Due to Diabetic Foot Ulcers Jan 08
Bonesupport Holding AB (publ) Announces Nomination Committee Changes Nov 29
Now 21% undervalued Nov 01
Erik Selin acquired 5.92% stake in Bonesupport Holding AB (publ) (OM:BONEX) from Odlander, Fredrikson & Co. AB. Oct 31 Bonesupport Holding AB (publ) to Report Q2, 2025 Results on Jul 15, 2025
Third quarter 2024 earnings released: EPS: kr0.47 (vs kr3.52 in 3Q 2023) Oct 25 See more updates
Bonesupport Holding AB (publ) Announces Study Results for CERAMENT G and CERAMENT V in Surgical Treatment of Bone Infection Due to Diabetic Foot Ulcers Jan 08
Bonesupport Holding AB (publ) Announces Nomination Committee Changes Nov 29
Now 21% undervalued Nov 01
Erik Selin acquired 5.92% stake in Bonesupport Holding AB (publ) (OM:BONEX) from Odlander, Fredrikson & Co. AB. Oct 31 Bonesupport Holding AB (publ) to Report Q2, 2025 Results on Jul 15, 2025
Third quarter 2024 earnings released: EPS: kr0.47 (vs kr3.52 in 3Q 2023) Oct 25
Now 23% undervalued Aug 05
Chief Executive Officer recently sold €1.6m worth of stock Jul 17
Second quarter 2024 earnings released: EPS: kr0.42 (vs kr0.08 in 2Q 2023) Jul 12 Bonesupport Holding AB (Publ) Appoints Anna Stegmark as EVP Quality Management & Regulatory Affairs, with Effect from 1 July 2024
Key Executive recently sold €312k worth of stock Jun 02
Insider recently sold €216k worth of stock May 19
First quarter 2024 earnings released Apr 26
Full year 2023 earnings released: EPS: kr3.77 (vs kr1.06 loss in FY 2022) Apr 22
Bonesupport Holding AB (Publ) Announces Resignation of Kristina Ingvar as Executive Vice President Quality Management & Regulatory Affairs Feb 23
Full year 2023 earnings released: EPS: kr3.77 (vs kr1.06 loss in FY 2022) Feb 18 Bonesupport Holding AB Provides Sales Guidance for the Year 2024 Nov 29
Investor sentiment improves as stock rises 28% Nov 02
Third quarter 2023 earnings released Oct 28 Bonesupport Holding AB (publ) to Report Q1, 2024 Results on Apr 25, 2024
New minor risk - Share price stability Oct 26
Bone Support Receives “Breakthrough Device Designation” for Cerament® V for the Indication of Bone Infection Oct 17
Independent Director recently bought €91k worth of stock Aug 03
Second quarter 2023 earnings released: EPS: kr0.08 (vs kr0.25 loss in 2Q 2022) Jul 14
BONESUPPORT Holding AB Announces Strong Long-Term Results with CERAMENT®G for Severe Open Fractures May 26
Insider recently sold €62k worth of stock May 17
Forecast breakeven date moved forward to 2023 May 15
Chief Executive Officer recently sold €1.3m worth of stock May 05
Full year 2022 earnings released: kr1.06 loss per share (vs kr1.34 loss in FY 2021) Apr 24
Insider recently sold €120k worth of stock Mar 17
Full year 2022 earnings released: kr1.06 loss per share (vs kr1.34 loss in FY 2021) Feb 18
Bonesupport Holding AB (publ), Annual General Meeting, Nov 21, 2023 Jan 24
No independent directors Nov 16 Bonesupport Holding AB (publ) to Report Q3, 2023 Results on Oct 26, 2023
Third quarter 2022 earnings released Oct 28
No longer forecast to breakeven Oct 26
Bonesupport's CERAMENT G Used in First U.S. Patient Cases Oct 26
An unknown buyer acquired unknown minority stakes in Bonesupport Holding AB (publ) (OM:BONEX) from Helena Brandt for SEK 0.84 million. Sep 25
Bonesupport Holding AB (publ) Announces Publication of Mid- to Long-Term Data Confirming the Sustained Clinical Effectiveness of CERAMENT G Sep 09
Second quarter 2022 earnings released: kr0.25 loss per share (vs kr0.42 loss in 2Q 2021) Jul 15
Forecast breakeven date moved forward to 2023 Jun 01
BONESUPPORT Receives Market Authorization for CERAMENT G in the US May 19
Forecast breakeven date pushed back to 2024 May 18
Chairman of the Board recently bought €117k worth of stock May 12
Forecast breakeven date pushed back to 2024 May 09
Less than half of directors are independent Apr 27
Full year 2021 earnings released: kr1.34 loss per share (vs kr1.72 loss in FY 2020) Apr 15
Bonesupport Holding AB (publ) to Report Fiscal Year 2021 Final Results on Apr 13, 2022 Apr 14
BONESUPPORT(TM) Announces Delays Within FDA Postpones CERAMENT G De Novo Decision Mar 01
Forecast breakeven date pushed back to 2024 Feb 20
Full year 2021 earnings: EPS in line with expectations, revenues disappoint Feb 18
Executive Vice President of Manufacturing & Supply Johan Olsson has left the company Dec 01
Executive VP of Medical & Clinical Affairs and Chief Medical Officer Michael Diefenbeck has left the company Dec 01
Third quarter 2021 earnings released Nov 06
Bonesupport Announces Supplementary US Denovo Application Submitted Sep 29
Forecast to breakeven in 2023 Sep 23
Bonesupport Announces Study Results for its Investigational Device Exemption(IDE) Study, Fortify Sep 10
Forecast to breakeven in 2023 Sep 10
Chief Financial Officer recently bought €8.5k worth of stock Aug 14
Executive VP of R&D recently sold €59k worth of stock Aug 03
Chairman of the board recently bought €157k worth of stock Jul 20
Second quarter 2021 earnings released Jul 17
No longer forecast to breakeven Jun 29
BONESUPPORTTM Receives Device Designation for CERAMENT G for the Indication Trauma Jun 18
Forecast to breakeven in 2023 May 17
First quarter 2021 earnings released May 08
Full year 2020 earnings released: kr1.72 loss per share (vs kr3.10 loss in FY 2019) Apr 17
Chief Executive Officer recently bought €40k worth of stock Mar 10
New 90-day low: €5.70 Mar 02
Bonesupport Holding AB (publ) Receives Notification from the US Food and Drug Administration Feb 28
Full year 2020 earnings released: kr1.72 loss per share (vs kr3.10 loss in FY 2019) Feb 19
Revenue beats expectations Feb 19
Executive VP of R&D recently bought €6.8k worth of stock Jan 18
New 90-day high: €7.40 Dec 24
Bonesupport Holding AB (Publ) Announces Resignation of Simon Cartmell from the Board of Directors Nov 20
Revenue beats expectations Nov 07
Third quarter 2020 earnings released: kr0.33 loss per share Nov 07 Bonesupport Holding AB (publ) to Report First Half, 2021 Results on Jul 15, 2021
New 90-day high: €6.70 Nov 05
New 90-day high: €6.52 Oct 19
New 90-day high: €6.48 Oct 01 Shareholder Returns 2B4 DE Biotechs DE Market 7D -7.0% -1.8% 1.8% 1Y 64.2% -5.0% 12.6%
See full shareholder returns
Return vs Market: 2B4 exceeded the German Market which returned 12.6% over the past year.
Price Volatility Is 2B4's price volatile compared to industry and market? 2B4 volatility 2B4 Average Weekly Movement 6.2% Biotechs Industry Average Movement 6.1% Market Average Movement 4.8% 10% most volatile stocks in DE Market 11.1% 10% least volatile stocks in DE Market 2.3%
Stable Share Price: 2B4 has not had significant price volatility in the past 3 months compared to the German market.
Volatility Over Time: 2B4's weekly volatility (6%) has been stable over the past year.
About the Company Bonesupport Holding AB (publ), an orthobiologics company, develops and commercializes injectable bio-ceramic bone graft substitutes in Europe, North America, and internationally. The company provides CERAMENT Bone Void Filler, an injectable ceramic bone graft substitute that remodels to host bone; CERAMENT G, an injectable ceramic bone graft substitute that remodels to host bone and elutes Gentamicin during the critical first 30 days of bone healing, as well as treats and prevents bone infection; CERAMENT V, an injectable ceramic bone graft substitute that remodels to host bone and elutes Vancomycin during the critical first 30 days of bone healing, as well as treats and prevents bone infection. It also offers CERAMENT Bead Tray, an adjunctive local delivery option for surgeons for targeted delivery to osseous defects and for dead space management.
Show more Bonesupport Holding AB (publ) Fundamentals Summary How do Bonesupport Holding's earnings and revenue compare to its market cap? 2B4 fundamental statistics Market cap €1.97b Earnings (TTM ) €7.90m Revenue (TTM ) €71.04m
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) 2B4 income statement (TTM ) Revenue SEK 814.46m Cost of Revenue SEK 61.64m Gross Profit SEK 752.82m Other Expenses SEK 662.24m Earnings SEK 90.58m
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
Feb 25, 2025
Earnings per share (EPS) 1.38 Gross Margin 92.43% Net Profit Margin 11.12% Debt/Equity Ratio 0%
How did 2B4 perform over the long term?
See historical performance and comparison
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2025/01/26 23:25 End of Day Share Price 2025/01/24 00:00 Earnings 2024/09/30 Annual Earnings 2023/12/31
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources Bonesupport Holding AB (publ) is covered by 4 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst Institution Maria Vara Fernández Bryan Garnier & Co Kristofer Liljeberg-Svensson Carnegie Investment Bank AB Jonas Peciulis Edison Investment Research
Show 1 more analysts 
